The tweet was deleted by the author.
But we saved everything 🙂.
Michael Taylor, co-founder and portfolio manager at Agora Trading, highlights that UTHR may have an important new product story emerging in 2027.
He also humorously remarks about the possibility of a pig that could solve organ transplant challenges.
View post on X Loading...
Taylor has recently commented on AQRT’s Phase 2 Vitiligo study targeting a $1 billion market in 2026. He has also covered the $2 billion preferred convertible agreement between Summit Therapeutics and AstraZeneca in lung cancer therapies. These updates reflect Taylor’s ongoing focus on new product developments and major biotech transactions.